Securities Code: 300558
Securities Abbreviation: Betta Pharmaceuticals
Announcement No.: 2026-049
Betta Pharmaceuticals Co., Ltd.
Announcement on the Results of the Second Vesting Period of the First Tranche and the First Vesting Period of the Reserve Tranche of the 2023 Restricted Stock Incentive Plan and the Listing of Shares
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Key Information Prompt:
-
Vesting Date: August 3, 2026
-
Number of Shares to be Vested: A total of 2,597,842 shares will be vested, accounting for 0.62% of the Company's current total share capital of 42,073.3843 million shares. Of these, 2,025,313 shares are from the initial grant, accounting for 0.48% of the Company's current total share capital of 42,073.3843 million shares; and 572,529 shares are from the reserve grant, accounting for 0.14% of the Company's current total share capital of 42,073.3843 million shares.
-
Number of Employees to Vest Shares: 544 individuals, including 415 from the initial grant and 129 from the reserve grant. Due to 5 incentive recipients holding both initial and reserve grant rights, the number of registered individuals at China Securities Depository and Clearing Corporation Limited is 539.
-
Listing and Circulation Arrangement for Vested Shares: The number of shares to be listed and circulated is 2,597,842, accounting for 0.62% of the Company's current total share capital of 42,073.3843 million shares. The listing and circulation date for these shares is August 3, 2026. There are no other restrictions on the vested restricted shares, and they can be circulated upon listing.
I. Overview of the Implementation of the Equity Incentive Plan
(I) Main Content of the Incentive Plan
The Company's Fourth Board of Directors' Tenth Meeting held on November 17, 2023, and the First Extraordinary Shareholders' Meeting of 2023 held on December 5, 2023, deliberated and approved the "Betta Pharmaceuticals Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)" (hereinafter referred to as the "2023 Incentive Plan (Draft)") and related proposals. The main content is as follows:
-
Incentive Tool: Second Class Restricted Shares.
-
Source of Underlying Shares: A ordinary shares issued by the Company to incentive recipients on a targeted basis.
-
Grant Price: RMB 41.17 per share.
-
Number of Restricted Shares: The total number of second class restricted shares to be granted to incentive recipients under this incentive plan is 13.32549 million shares, accounting for 3.18% of the Company's total share capital of 418.485885 million shares at the time of the announcement of this incentive plan. Among them, the initial grant is 11.10549 million shares, accounting for 83.34% of the total equity to be granted under the incentive plan and 2.65% of the Company's total share capital of 418.485885 million shares at the time of the announcement of this incentive plan; the reserve grant is 2.22 million shares, accounting for 16.66% of the total equity to be granted under the incentive plan and 0.53% of the Company's total share capital of 418.485885 million shares at the time of the announcement of this incentive plan.
-
Number of Incentive Recipients: The total number of incentive recipients for the initial grant under this incentive plan is 675, including directors, senior management, other management personnel, and core technical (business) personnel of the Company and its subsidiaries (excluding independent directors and supervisors).
-
The term of this incentive plan shall be from the date of the initial grant of restricted shares to the date when all restricted shares granted to the incentive recipients are vested or become void due to expiration, whichever is the longest, not exceeding 48 months.